Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Executive Summary
Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.
You may also be interested in...
COVID-19 Gives Gilead A Down Quarter, But Guidance Boosted By Remdesivir
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.
Remdesivir Should Give Gilead’s 2020 Revenue A Needed Lift
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
Stockwatch: Gilead, BMS Expose High Cost Of M&A
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports